Sutro Biopharma, Inc.
$34.58
▼
-4.38%
2026-04-21 09:38:02
www.sutrobio.com
NGM: STRO
Explore Sutro Biopharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$572.9 M
Current Price
$34.58
52W High / Low
$34.58 / $5.23
Stock P/E
—
Book Value
$-15.43
Dividend Yield
—
ROCE
-106.34%
ROE
435.02%
Face Value
—
EPS
$-22.49
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
137
Beta
1.31
Debt / Equity
-0.12
Current Ratio
2.01
Quick Ratio
2.01
Forward P/E
-10.43
Price / Sales
4.18
Enterprise Value
$302.67 M
EV / EBITDA
-3.1
EV / Revenue
2.95
Rating
Buy
Target Price
$30.11
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Curanex Pharmaceuticals Inc | $0.48 | — | $12.79 M | — | -37.04% | -85.25% | $9.18 / $0.26 | $0.01 |
| 2. | Zenas BioPharma, Inc. | $20.9 | — | $1.28 B | — | -65.85% | -1.36% | $44.6 / $8.09 | $4.44 |
| 3. | Geron Corporation | $1.56 | — | $1.02 B | — | -11.23% | -32.99% | $2.01 / $1.04 | $0.35 |
| 4. | Galectin Therapeutics Inc. | $2.29 | — | $156.67 M | — | -174.62% | 26.9% | $7.13 / $1.21 | $-1.97 |
| 5. | Definium Therapeutics, Inc. | $23.18 | — | $2.26 B | — | -44.54% | -64.06% | $23.41 / $5.36 | $3.36 |
| 6. | Karyopharm Therapeutics Inc. | $8.94 | — | $193.06 M | — | -554.58% | 81.86% | $10.99 / $3.65 | $-16 |
| 7. | Eledon Pharmaceuticals, Inc. | $4.14 | — | $314.03 M | — | -55.26% | -35.79% | $4.6 / $1.35 | $1.81 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 11.65 M | 9.69 M | 63.74 M | 17.4 M | 14.81 M | — |
| Operating Profit | -33.66 M | -38.9 M | 15.08 M | -47.47 M | -65.26 M | — |
| Net Profit | -46.76 M | -56.86 M | -11.5 M | -75.97 M | -72.44 M | — |
| EPS in Rs | -2.82 | -3.43 | -0.69 | -4.59 | -4.37 | -5.9 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 102.48 M | 62.04 M | 153.73 M | 67.77 M |
| Operating Profit | -104.95 M | -238.45 M | -89.28 M | -128.94 M |
| Net Profit | -191.09 M | -227.46 M | -106.79 M | -119.2 M |
| EPS in Rs | -11.53 | -13.73 | -6.45 | -7.2 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 173.83 M | 387.21 M | 470.74 M | 406.94 M |
| Total Liabilities | 306.28 M | 342.61 M | 321.09 M | 189.9 M |
| Equity | -132.45 M | 44.6 M | 149.65 M | 217.05 M |
| Current Assets | 150.93 M | 343.31 M | 421.54 M | 353.15 M |
| Current Liabilities | 75.13 M | 131.89 M | 93.75 M | 66.55 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -177.23 M | -191.54 M | -111.62 M | 3.55 M |
| Investing CF | 45.01 M | 218.51 M | -3.92 M | -35.02 M |
| Financing CF | 0.04 M | 94.05 M | 137.55 M | 48.31 M |
| Free CF | -178.93 M | -194.64 M | -115.93 M | -4.31 M |
| Capex | -1.7 M | -3.1 M | -4.32 M | -7.86 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -59.64% | 126.84% | — | — |
| Earnings Growth % | -112.99% | 10.41% | — | — |
| Profit Margin % | -366.62% | -69.47% | -175.89% | — |
| Operating Margin % | -384.34% | -58.07% | -190.26% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -301.1% | -37.75% | -158.87% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-12-03 | 1:0.1 |